Insulin inhibits glucocorticoid-stimulated L-type 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene expression by activation of the c-Jun N-terminal kinase pathway

Biochem J. 2001 Jan 15;353(Pt 2):267-73. doi: 10.1042/0264-6021:3530267.

Abstract

The hepatic isoform of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PF2K/Fru-2,6-BPase) is transcriptionally stimulated by glucocorticoids, whereas insulin blocks this stimulatory effect. Although this inhibitory effect has been extensively reported, nothing is known about the signalling pathway responsible. We have used well-characterized inhibitors for proteins involved in different signalling cascades to assess the involvement of these pathways on the transcriptional regulation of glucocorticoid-stimulated PF2K/Fru-2,6-BPase by insulin. Our results demonstrate that the phosphoinositide 3-kinase, p70/p85 ribosomal S6 kinase, extracellular signal-regulated protein kinase (ERK)1/2 and p38 mitogen-activated protein (MAP) kinase pathways are not involved in the inhibitory effect of insulin on glucocorticoid-stimulated PF2K/Fru-2,6-BPase. To evaluate the implication of the MAP kinase/ERK kinase (MEK)-4-stress-activated protein kinase-c-Jun-N-terminal protein kinase ('JNK-SAPK') pathway we overexpressed the N-terminal JNK-binding domain of the JNK-interacting protein 1 ('JIP-1'), demonstrating that activation of JNK is necessary for the insulin inhibitory effect. Moreover, overexpression of MEK kinase 1 and JNK-haemagglutinin resulted in the inhibition of the glucocorticoid-stimulated PF2K/Fru-2,6-BPase. These results provide clear and specific evidence for the role of JNK in the insulin inhibition of glucocorticoid-stimulated PF2K/Fru-2,6-BPase gene expression. In addition, we performed experiments with a mutant of the glucocorticoid receptor in which the JNK phosphorylation target Ser-246 had been mutated to Ala. Our results demonstrate that the phosphorylation of the glucocorticoid receptor on Ser-246 is not responsible for the JNK repression of glucocorticoid-stimulated PF2K/Fru-2,6-BPase gene expression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Chromones / pharmacology
  • Dexamethasone / antagonists & inhibitors
  • Dexamethasone / pharmacology
  • Enzyme Inhibitors / pharmacology
  • Flavonoids / pharmacology
  • Fructose-Bisphosphatase / antagonists & inhibitors
  • Fructose-Bisphosphatase / biosynthesis*
  • Fructose-Bisphosphatase / genetics
  • Gene Expression Regulation / drug effects
  • Insulin / pharmacology*
  • JNK Mitogen-Activated Protein Kinases
  • Mitogen-Activated Protein Kinases / antagonists & inhibitors
  • Mitogen-Activated Protein Kinases / metabolism*
  • Morpholines / pharmacology
  • Multienzyme Complexes / antagonists & inhibitors
  • Multienzyme Complexes / biosynthesis*
  • Multienzyme Complexes / genetics
  • Phosphofructokinase-1 / antagonists & inhibitors
  • Phosphofructokinase-1 / biosynthesis*
  • Phosphofructokinase-1 / genetics
  • Phosphofructokinase-2
  • Plasmids
  • RNA, Messenger / analysis
  • Rats
  • Signal Transduction
  • Sirolimus / pharmacology
  • Transfection
  • Tumor Cells, Cultured

Substances

  • Chromones
  • Enzyme Inhibitors
  • Flavonoids
  • Insulin
  • Morpholines
  • Multienzyme Complexes
  • RNA, Messenger
  • 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
  • Dexamethasone
  • Phosphofructokinase-2
  • Phosphofructokinase-1
  • JNK Mitogen-Activated Protein Kinases
  • Mitogen-Activated Protein Kinases
  • Fructose-Bisphosphatase
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one
  • Sirolimus